Determinants of serum antipyrine half-lives in patients with liver disease
Open Access
- 1 July 1973
- Vol. 14 (7) , 569-573
- https://doi.org/10.1136/gut.14.7.569
Abstract
Antipyrine has been used as a model drug to investigate the effects of liver disease on drug metabolism in man. A prolongation in antipyrine half-life (T½) was found in patients with liver disease, patients with chronic liver disease showing a greater increase than those with acute, reversible pathology. The most marked prolongation in T½ was found in association with hypoalbuminaemia and hypoprothrombinaemia, suggesting that the cause for these changes was defective protein synthesis of microsomal enzyme protein. This hypothesis was supported by demonstrating that enzyme-inducing agents, which are known to increase the amount of microsomal enzyme protein, reduced the antipyrine half-life.Keywords
This publication has 14 references indexed in Scilit:
- Influence of nitrazepam on oral anticoagulation with phenprocoumonClinical Pharmacology & Therapeutics, 1972
- Metabolism of amylobarbitone in patients with chronic liver diseaseBritish Journal of Pharmacology, 1972
- Kinetics of rifampicin and isoniazid administered alone and in combination to normal subjects and patients with liver diseaseGut, 1972
- Interrelationships of Hepatic Blood Flow, Cardiac Output, and Blood Levels of Lidocaine in ManCirculation, 1971
- Genetic control of the phenobarbital-induced shortening of plasma antipyrine half-lives in manJournal of Clinical Investigation, 1969
- PHENYLBUTAZONE AND ISONIAZID METABOLISM IN PATIENTS WITH LIVER DISEASE IN RELATION TO PREVIOUS DRUG THERAPYThe Lancet, 1968
- RATE OF METABOLISM OF TOLBUTAMIDE IN TEST SUBJECTS WITH LIVER DISEASE OR WITH IMPAIRED RENAL FUNCTIONThe Lancet Healthy Longevity, 1964
- PERSISTENCE OF ANTIBIOTICS IN BLOOD OF PATIENTS WITH ACUTE RENAL FAILURE. II. CHLORAMPHENICOL AND ITS METABOLIC PRODUCTS IN THE BLOOD OF PATIENTS WITH SEVERE RENAL DISEASE OR HEPATIC CIRRHOSIS*†Journal of Clinical Investigation, 1959
- Metabolism of Drugs in Subjects with Laennec’s CirrhosisPharmacology, 1959
- OBSERVATIONS ON THE METABOLIC TRANSFORMATION AND EFFECTS OF PHENYLBUTAZONE IN SUBJECTS WITH HEPATIC DISEASEThe Lancet Healthy Longevity, 1954